Ignite Creation Date:
2024-05-05 @ 11:22 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00002290
Status:
COMPLETED
Last Update Posted:
2005-06-24
First Post:
1999-11-02
Brief Title:
The Safety and Effectiveness of Zidovudine Plus Acyclovir in Patients With Early HIV Infection
Sponsor:
Glaxo Wellcome
Organization:
NIH AIDS Clinical Trials Information Service
Study Overview
Official Title:
A Multi-Center Double-Blind Trial to Evaluate the Safety and Efficacy of Concurrent Retrovir Zidovudine and Zovirax Acyclovir Therapy in Patients With Early Symptomatic Human Immunodeficiency Virus HIV Infection
Status:
COMPLETED
Status Verified Date:
1990-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This double-blind placebo-controlled study is designed to determine the long-term safety and efficacy of concurrent oral Retrovir Zovirax AZT and ACV therapy and oral AZT therapy alone in the treatment of early symptomatic HIV infection Efficacy will be evaluated by monitoring the incidence severity and time of development of opportunistic infections and other manifestations of advanced symptomatic HIV infection The effects of the combination and single AZT therapy on immune function and viral replication will also be evaluated Study participants will be monitored for evidence of toxicity or intolerance to concurrent AZT ACV administration and AZT therapy alone
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 03 | None | None | None |